Healthcare / Drug Manufacturers - Specialty & GenericTSXV
$0.13
-0.01 (-7.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-148040.00 · quality 29.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-170.4%
↓Gross Margin
20.8%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+35.1%
FCF CAGR
—
FCF margin
7.0%
FCF / Net income
-0.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.0M · net income $-412313.0 · FCF $210605.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.0M | $3.0M | $3.9M | $3.2M | $1.2M |
| Net Income | $-412313.00 | $-412313.00 | $40603.00 | $-452140.00 | $-1.6M |
| EBITDA | $-390159.00 | $-390159.00 | $66239.00 | $-427193.00 | $-1.5M |
| EPS | -0.01 | -0.01 | 0.00 | -0.01 | -0.03 |
| Gross Margin | 20.8% | 20.8% | 31.5% | 21.0% | 18.8% |
| Operating Margin | -13.7% | -13.7% | 1.2% | -14.2% | -132.3% |
| Net Margin | -13.8% | -13.8% | 1.0% | -14.3% | -134.1% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.03 | 0.16 | 0.27 |
| Current Ratio | 1.22 | 1.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $210605.00 | $210605.00 | $-148040.00 | $-355129.00 | $-777776.00 |
| Returns | |||||
| ROE | -170.4% | -170.4% | 7.0% | -98.8% | -213.5% |
| Valuation | |||||
| P/E | — | — | 115.00 | — | — |
| EV/EBITDA | — | — | 87.30 | — | — |
| P/B | 26.46 | 26.46 | 10.23 | 18.26 | 3.82 |
| Growth & Yield | |||||
| Revenue Growth | -23.0% | -23.0% | 23.1% | 160.3% | — |
| EPS Growth | -900.0% | -900.0% | 111.1% | 73.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+160.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.00 → -0.01
Residual
+160.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.